The Protocol Review and Monitoring Committee (PRMC) provides full scientific review and monitors the progress of and accrual to all cancer clinical protocols Involving patients that are conducted in Dan L Duncan Cancer Center (DLDCC)-affiliated Institutions. PRMC functions are complementary to, but do not overlap those of the Data Safety Monitoring Committee and the IRB. The PRMS reviews all therapeutic and prevention clinical trials whose primary aim Is cancer related. The PRMC Is organized Into an Executive Committee and three working groups, with a total of 45 voting members. The Executive Committee chaired by Dr Stacey Berg the PRMC director assigns each protocol a scientific merit score of 1-9 based on NIH review descriptors as well as DLDCC priority scores of High, Medium, and Low at initial review to aid In prioritization. At the time of each open protocol's annual IRB review, the PRMC Executive Committee conducts a full review to ensure that adequate scientific progress is being made. In addition, the Executive Committee reviews the accrual to all the open protocols in each Program on a quarterly basis. In the 12 month period from July 2008 to June 2009 the PMRC reviewed 50 new protocols including 10 institutional protocols of which 6 were approved pending modification, 3 were tabled, and 1 was disapproved. The PMRC monitored 32 Institutional protocols during this period for performance closing 3 for slow accrual or because new scientific information lowered the priority of the study. The PRMC provides reports to the Clinical Research Leadership Committee which also receives reports from the Data Safety Monitoring Committees ensuring that activities of these two separate entitles are integrated.

Public Health Relevance

The Protocol Review and Monitoring Committee of the Dan L Duncan Cancer Center ensures that all clinical protocols at the center undergo a rigorous scientific review prior to opening and also monitors studies to ensure that they still have scientific relevance and are accruing subjects at the projected rate.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA125123-06
Application #
8376830
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
6
Fiscal Year
2012
Total Cost
$45,119
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Szwarc, Maria M; Kommagani, Ramakrishna; Putluri, Vasanta et al. (2018) Steroid Receptor Coactivator-2 Controls the Pentose Phosphate Pathway through RPIA in Human Endometrial Cancer Cells. Sci Rep 8:13134
Kruse, Robert L; Shum, Thomas; Tashiro, Haruko et al. (2018) HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy 20:697-705
Samaha, Heba; Pignata, Antonella; Fousek, Kristen et al. (2018) A homing system targets therapeutic T cells to brain cancer. Nature 561:331-337
Disney-Hogg, Linden; Sud, Amit; Law, Philip J et al. (2018) Influence of obesity-related risk factors in the aetiology of glioma. Br J Cancer 118:1020-1027
Su, Jianzhong; Huang, Yung-Hsin; Cui, Xiaodong et al. (2018) Homeobox oncogene activation by pan-cancer DNA hypermethylation. Genome Biol 19:108
Lu, Lianghao; Wen, Yefei; Yao, Yuan et al. (2018) Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21). Theranostics 8:2189-2201
Martini-Stoica, Heidi; Cole, Allysa L; Swartzlander, Daniel B et al. (2018) TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. J Exp Med 215:2355-2377
Wang, Changjun; Zaheer, Mahira; Bian, Fang et al. (2018) Sjögren-Like Lacrimal Keratoconjunctivitis in Germ-Free Mice. Int J Mol Sci 19:
Singh, Ramesh; Karri, Dileep; Shen, Hong et al. (2018) TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis. J Clin Invest 128:3129-3143
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746

Showing the most recent 10 out of 991 publications